Mesalazina Dorom (Mesalazine)

Mesalazine inhibits the cyclooxygenase and lipoxygenase pathways in the intestinal lining, decreasing the production of prostaglandins and leukotrienes. This reduction in inflammatory mediators lessens mucosal irritation and promotes healing of the colon.

The dosage of Mesalazina Dorom is individualized by the prescribing clinician based on disease severity, patient weight, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for mesalazine in pregnancy and lactation are limited. The prescriber must weigh potential benefits against possible risks. Women who are pregnant, planning pregnancy, or breastfeeding should discuss use with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Mesalazina Dorom belongs to the aminosalicylate class, offering a locally acting anti‑inflammatory option. Compared with systemic steroids or immunomodulators, it has a more favorable safety profile for long‑term maintenance but may be less potent for severe flares, where combination therapy might be required.

Store Mesalazina Dorom at room temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and discard any product that appears discoloured or damaged.

Mesalazina Dorom is taken orally, usually with water. The tablets can be swallowed whole or, if recommended by the prescriber, divided or crushed to aid swallowing, but patients should follow the specific instructions given by their healthcare professional.

Serious adverse events, though rare, include myocarditis, pericarditis, severe allergic reactions, blood dyscrasias such as neutropenia, and toxic colitis. Patients should seek immediate medical attention if they experience chest pain, severe rash, fever, or unexplained bleeding.

Individuals with known hypersensitivity to mesalazine, other aminosalicylates, or any component of the formulation should avoid this medication. It is also contraindicated in patients with severe renal or hepatic impairment unless closely monitored by a specialist.